Bioprocessing Technology Market Report 2025

This Bioprocessing Technology market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The bioprocessing technology market size has grown rapidly in recent years. It will grow from $25.1 billion in 2024 to $29.06 billion in 2025 at a compound annual growth rate (CAGR) of 15.8%. The growth in the historic period can be attributed to increasing demand for biopharmaceuticals, expansion of biotechnology and life sciences industries, growing investment in research and development, globalization of the biopharmaceutical market, focus on cost-efficiency and process optimization.

The bioprocessing technology market size is expected to see rapid growth in the next few years. It will grow to $49.92 billion in 2029 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to biomanufacturing capacity expansion, emergence of advanced therapies, rising importance of single-use bioprocessing systems, increased adoption of continuous bioprocessing, strategic collaborations and partnerships. Major trends in the forecast period include personalized medicine and precision bioprocessing, regulatory compliance and quality assurance, global expansion of biopharmaceutical production, environmental sustainability, collaborations and partnerships.

The rising incidence of chronic diseases is anticipated to significantly boost the growth of the bioprocessing technology market in the future. Chronic diseases are long-term health conditions that last for at least a year and can impair daily activities, necessitating ongoing medical care. Bioprocessing technologies are crucial for developing therapeutic proteins, polysaccharides, vaccines, and diagnostics essential for treating chronic diseases. Consequently, the growing prevalence of these diseases will drive the expansion of the bioprocessing technology market. For example, the World Health Organization, a United Nations agency based in Switzerland, projected in February 2024 that over 35 million new cancer cases will emerge by 2050, representing a 77% increase from the estimated 20 million cases in 2022. Thus, the rising incidence of chronic diseases is expected to propel the growth of the bioprocessing technology market.

The escalating healthcare expenditure is anticipated to fuel the expansion of the bioprocessing technology market. This expenditure encompasses resources allocated by individuals, organizations, or governments toward healthcare-related goods and services. Bioprocessing technology optimizes production processes within the healthcare sector, spanning pharmaceuticals and medical treatments. According to the CIHI in November 2022, Canada's health spending is projected to elevate by 0.8%, reaching $331 billion in 2022 from $328 billion in 2021. Hence, the surge in healthcare expenditure is a driving force behind the bioprocessing technology market.

Technological advancement stands out as a prominent trend shaping the bioprocessing technology market. Key industry players are channeling efforts into enhancing bioprocess technologies to maintain their market standing. Univercells Technologies Inc., in October 2022, introduced the scale-X cell collect module, a part of the scale-X technology. This innovation streamlines the inoculation process for large-scale bioreactors through automation and intensification, reducing costs, operating time, footprint, and aseptic risks while ensuring high repeatability.

Major entities in the bioprocessing technology domain are dedicated to developing comprehensive bioprocessing solutions, such as bioprocessing platforms, to meet the increasing demand for enhanced yields and maximize profitability. Bioprocessing platforms encompass technologies and methods tailored for efficient large-scale biological material processing, especially in producing biopharmaceuticals. For instance, WuXi Biologics introduced WuXiUI in October 2023, a high-productivity bioprocessing platform enhancing mammalian cell line productivity and product quality. Utilizing an ultra-intensified intermittent-perfusion fed-batch strategy, WuXiUI achieves 3 to 6-fold productivity increases compared to conventional processes, catering to the need for yield enhancement, cost reduction, and adherence to environmental, social, and governance (ESG) considerations in bioprocess development.

In August 2024, Merck KGaA, a science and technology company based in Germany, acquired Mirus Bio for $600 million. This acquisition is intended to strengthen Merck KGaA's viral vector bioprocessing capabilities, allowing the company to offer integrated solutions across the entire manufacturing spectrum, from preclinical stages to commercial production. Mirus Bio, a biotechnology company located in the U.S., specializes in delivering innovative solutions for life sciences research and gene delivery applications.

Bioprocessing technology involves utilizing microbes, living cells, or components of living organisms to synthesize various biological products. This versatile process finds application in producing chemicals, food items, flavors, fuels, and medications, leveraging biocatalysts such as enzymes and microbes.

The primary products associated with bioprocessing technology include biologics safety testing, cell culture, cell expansion, cell line development, flow cytometry, and tangential flow filtration. Biologics safety testing encompasses a series of tests and protocols employed to assess the safety of biological products such as vaccines, gene therapies, and blood products before their approval for human use. These tests evaluate purity, potency, identity, and stability of these products. Bioprocess technology is utilized in antibiotics, biosimilars, recombinant proteins, and various other applications. It finds application across biopharmaceutical companies, contract manufacturing organizations, academic research institutes, the food and feed industry, as well as contract research organizations.

The bioprocessing technology software market research report is one of a series of new reports that provides bioprocessing technology software market statistics, including bioprocessing technology software industry global market size, regional shares, competitors with a bioprocessing technology software market share, detailed bioprocessing technology software market segments, market trends and opportunities, and any further data you may need to thrive in the bioprocessing technology software industry. This bioprocessing technology software market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Major companies operating in the bioprocessing technology market report are Thermo Fisher Scientific Inc., Sartorius AG, Merck KGaA, Danaher Corporation, Lonza Group AG, GE Healthcare, Waters Corporation, STADA Arzneimittel AG, Bio-Rad Laboratories Inc., Applikon Biotechnology B.V., Agilent Technologies Inc., Solida Biotech GmbH, Fujifilm Healthcare Corporation, Catalent Inc., Asahi Kasei Medical Inc., Amgen Inc., Eppendorf AG, Repligen Corporation, Becton Dickinson and Company, MilliporeSigma, Novasep, Boehringer Ingelheim GmbH, Cytiva AB, Wuxi Biologics, AGC Biologics, Samsung Biologics, AbbVie Inc., Bristol Myers Squibb Company, Pfizer Inc., Roche Holding AG.

North America was the largest region in the bioprocessing technology market in 2024. The regions covered in the bioprocessing technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bioprocessing technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The bioprocess technology market includes revenues earned by entities through media preparation, biocatalyst optimization, mass production, downstream processing, and purification. The market value includes the value of related goods sold by the service provider or included within the service offering. The bioprocess technology market also includes sales of process columns, dispersers or emulsifiers, screens or sieves, filters, fermenters or bioreactors, and process homogenizers which are used in bioprocess technology. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.